(Q35024736)

5 August 2017

1 reference

title

Challenging the platinum combinations in the chemotherapy of NSCLC. (English)

1 reference

5 August 2017

1 reference

J-Y Douillard

1

1 reference

5 August 2017

J Eckardt

series ordinal

2

1 reference

5 August 2017

G V Scagliotti

series ordinal

3

1 reference

5 August 2017

publication date

1 December 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

38 Suppl 4

1 reference

5 August 2017

page(s)

21-28

1 reference

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900168-X

7 January 2021

Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900168-X

7 January 2021

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900168-X

7 January 2021

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900168-X

7 January 2021

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900168-X

7 January 2021

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900168-X

7 January 2021

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900168-X

7 January 2021

Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900168-X

7 January 2021

Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900168-X

7 January 2021

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900168-X

7 January 2021

New directions in the treatment of non-small cell lung cancer: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900168-X

7 January 2021

Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900168-X

7 January 2021

Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900168-X

7 January 2021

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900168-X

7 January 2021

Camptothecin analogues in the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900168-X

7 January 2021

10.1016/S0169-5002(02)00168-X

Identifiers

DOI

1 reference

5 August 2017

1 reference